**DEVELOPMENT,      MANUFACTURING AND SUPPLY AGREEMENT**

**RECITALS**

| A. | CTI                owns or has licensed certain patented technology (US Patent # * and                # *,                Applications # * and # * and PCT Application # *), relating to the                use of                * to treat overuse * (as defined below, the “Clinical Trial                Products”). |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| B. | Hercon                will perform development and related manufacturing services for CTI                leading to the manufacture of Clinical Trial                Products. |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**ARTICLE      1**

**DEFINITIONS**

| 1.1 | “**Affiliate**”                shall mean, with respect to any party, any person or entity which,                directly or indirectly through one or more intermediaries, controls,                is                controlled by, or is under common control with, such party. A person                or                entity shall be deemed to control a corporation (or other entity)                if such                person or entity possesses, directly or indirectly, the power to                direct or                cause the direction of the management and policies of such corporation                (or                other entity) whether through the ownership of voting securities,                by                contract or otherwise. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.2 | “**Nitroglycerin                Adhesive Mixture**”                shall mean the adhesive mixture containing nitroglycerin as the active                ingredient sourced from a third party base                supplier. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.3 | “**Clinical                Trial Products**”                shall mean the formulations, and only such formulations as supplied                by                CTI, of Nitroglycerin Adhesive Mixture in such strengths as shall                provide                for delivery of * mg/hour to * mg/hour of GTN (glyceryl trinitrate)                (and                such other delivery strengths as the Parties may agree upon in writing)                in                patch form for transdermal administration to meet the Product                Specifications. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.4 | “**Product                Specifications**”                shall mean the specifications for the Clinical Trial Products as                shall be                mutually agreed between the parties in writing and attached as Exhibit                A                hereto, and shall include (as applicable) statements of pharmaceutical                manufacturing, filling, storage and quality control procedures, and                labeling and packaging specifications (as such may be revised from                time to                time in accordance with the terms of this Agreement by written agreement                executed by the parties). |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1.5 | “**Confidential                Information**”                shall mean, with respect to a party, all information of any kind                whatsoever (including without limitation, the Intellectual Property,                data,                compilations, formulae, models, patent disclosures, procedures, processes,                projections, protocols, results of experimentation and testing,                specifications, strategies and techniques), and all tangible and                intangible embodiments thereof of any kind whatsoever (including                without                limitation, apparatus, compositions, documents, drawings, machinery,                patent applications, records and reports), which is disclosed by                such                party to the other party and is marked, identified as or otherwise                acknowledged in written or tangible form to be confidential at the                time of                disclosure to the other party. Notwithstanding the foregoing, Confidential                Information of a party shall not include information which the other                party                can establish by written documentation (a) to have been publicly                known                prior to disclosure of such information by the disclosing party to                the                other party, (b) to have become publicly known, without fault on                the part                of the other party, subsequent to disclosure of such information                by the                disclosing party to the other party, (c) to have been received by                the                other party at any time from a source, other than the disclosing                party,                rightfully having possession of and the right to disclose such                information, (d) to have been otherwise known by the other party                prior to                disclosure of such information by the disclosing party to the other                party,                or (e) to have been independently developed by employees or agents                of the                other party without the use of such information disclosed by the                disclosing party to the other                party. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.6 | “**Drug                Master File**”                shall mean the Drug Master File for manufacturing the active                pharmaceutical ingredient or other raw materials used in the Clinical                Trial Products, filed with the FDA, and the equivalent filing with                any                other country, as same may be amended from time to                time. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.7 | “**FDA**”                shall mean the United States Food and Drug Administration, and any                successor agency thereto. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.8 | “**GMP**”                shall mean current Good Manufacturing Practices promulgated by the                FDA,                and their equivalent promulgated by the governing health authority                of any                other country in which the Clinical Trial Products manufactured by                Hercon                under this Agreement are to be sold by CTI, as the same may be amended                from time to time. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.9 | “**Intellectual                Property**”                shall mean rights, including, without limitation, any licensed rights,                existing as of the date hereof and as may be developed hereafter                in and to                all confidential or proprietary information, trade secrets, patent                rights,                technology, know-how, developments, improvements, techniques, data,                methods, processes, instructions, formulae, recipes, drawings and                specifications necessary to manufacture and supply the Clinical Trial                Products hereunder. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.10 | “**Label**”,                “**Labeled**”                or “**Labeling**”                shall mean (i) all labels and other written, printed or graphic matter                upon the Clinical Trial Products or upon any container or wrapper                utilized                with the Clinical Trial Products, or (ii) any written material                accompanying the Clinical Trial Products, including, without limitation,                package inserts. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1.11 | “**Limited                Warranty**”                shall have the meaning defined in Section 4.4(c)                hereof. |
|------|------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| 1.12 | “**Packaging**”                shall mean all primary containers, cartons, shipping cases or any                other                like matter used in packaging or accompanying the Clinical Trial                Products. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.13 | “**Parties**”                shall mean CTI and Hercon and their respective successors and assigns. |
|------|-----------------------------------------------------------------------------------------------------------------|

| 1.14 | “**Person**”                shall mean an individual, corporation, partnership, limited liability                company, trust, business trust, association, joint stock company,                joint                venture, pool, syndicate, sole proprietorship, unincorporated                organization, governmental authority or any other form of entity                not                specifically listed herein. |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.15 | “**Product                NDA**”                shall mean the New Drug Application relating to the Clinical Trial                Products as may be filed with the FDA by CTI, and any supplements                thereto. |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.16 | “**Regulatory                Dossiers**”                shall mean all registrations, permits, licenses, authorizations,                approvals, presentations, notifications or filings (together with                all                applications therefor), if any, which are filed with or granted by                the                governing health authority of any country, including the FDA, and                which                are required to develop, make, use, sell, import or export the Clinical                Trial Products, other than the Drug Master                File. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.17 | “**Territory**”                shall mean the United States of America (including all of its states,                Puerto Rico, the District of Columbia, and all territories, dependencies,                and possessions of the United States) and such additional countries                as may                be added from time to time by mutual written agreement of the parties                hereto. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.18 | “**Process**”                or “**Processing**”                shall mean the act of manufacturing, handling, storing, analyzing,                testing, filling, finishing, packaging, inspecting, labeling and                preparing                for shipment of Clinical Trial Products by Hercon pursuant to this                Agreement and shall include, without limitation, optimization of                the                formulation of or process by which the Clinical Trial Products are                made.                Processing shall also include all tasks and services set forth on                Exhibit                B hereto. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**ARTICLE      2**

**OBLIGATIONS**

| 2.1 | **Obligations                of Hercon**.                Hercon shall perform all Processing, including all tasks and services                set                forth on Exhibit B hereto, in accordance with this Agreement. Without                limiting the generality of the foregoing, Hercon’s obligations shall                include the following: |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | **Regulatory                Compliance**.                Promptly upon execution of this Agreement, Hercon shall apply for                or                extend, and throughout the term of this Agreement Hercon shall maintain                and remain in compliance with, all Regulatory Dossiers required in                the                Territory for Hercon’s Processing of the Clinical Trial Products                hereunder, including all necessary licenses, permits and approvals                required by the FDA and/or other regulatory agencies in connection                with                the manufacture, filling, packaging, storage, and shipment of the                Clinical                Trial Products. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (b) | **Reporting**.                Hercon shall keep CTI fully informed of the status of the Processing                of                the Clinical Trial Products including providing written reports at                reasonable frequencies to CTI upon request, stating in reasonable                detail                all efforts made and in process, and all significant progress achieved                and                material difficulties encountered in the Processing of the Clinical                Trial                Products since the last such report. In addition, verbal reporting                can be                regularized, such as every week or every other week, upon CTI’s request.                Hercon shall (i) provide CTI with access to all technical information                employed in or arising out of Hercon’s Processing of the Clinical Trial                Products; and (ii) provide such other information concerning the                Processing of Clinical Trial Products as CTI shall reasonably request.                Hercon will designate a primary project contact with respect to the                Clinical Trial Products throughout the performance of the Processing                of                the Clinical Trial Products pursuant to this Section 2.1 to answer                any                reasonable questions from CTI. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | **Generation                and Maintenance of Data and Records for Product NDA Filing and as                Required                by Law**.                Hercon shall be responsible for generation and maintenance of all                product                manufacturing related data required for the filing by CTI of the                Product                NDA with the FDA, including, without limitation, data relating to                product                specifications, analytical methods, stability data, process validation                and                manufacturing processes and instructions. Upon the reasonable request                of                CTI, Hercon promptly shall provide CTI with such information, samples                and                technical assistance, and otherwise cooperate with CTI, in connection                with                the preparation, prosecution and maintenance of the Product NDA.                In                addition, Hercon shall maintain, for a period of at least three (3)                years                from the manufacturing date or longer if required under applicable                laws or                regulations, complete, true and accurate books, records, test and                laboratory data, reports and all other information relating to the                services performed by Hercon under this Agreement, including technical                records pertaining to the methods, facilities and equipment used                for                Processing of Clinical Trial Products, in accordance with all applicable                laws and regulations. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.2 | **Milestone                Payments to Hercon.**                Subject to the achievement of the applicable milestones provided                in                Section 3.1, in consideration of technology transfer review, formulation                optimization and scale-up work, Clinical Trial Products manufacture                and                other services to be performed by Hercon under this Agreement, CTI                shall                pay Hercon the milestone payments set forth in Section 3.1, provided                the                scope of the project with respect to the clinical supplies outlined                in                Exhibit C does not change. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.3 | **Funding                of the Safety and Efficacy Studies by CTI.**CTI                shall, at its own cost and expense, engage a contract research                organization to conduct the safety and efficacy studies of Clinical                Trial                Products. In the event that the study fails to demonstrate the safety                or                the efficacy of the Clinical Trial Products, then CTI shall have                the right                to terminate this Agreement as provided in Section                11.2. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 2.4 | **Filing                of a Product NDA.**                Subject to Hercon’s assistance as set forth in Section 2.1 above, CTI                shall, at its own cost and expense, prepare, file and prosecute the                Product NDA with the FDA. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**ARTICLE      3**

**MILESTONE      PAYMENTS; PRICE AND PAYMENT TERMS**

| 3.1 | **Milestone                Payments**.                For                the services rendered to CTI by Hercon under this                Agreement, CTI shall remit to Hercon the following milestone payments: |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                              |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|
| **MILESTONE**                                                                                                                                                                                                                                                                                                                                                                                                                                                            | **PAYMENT                AMOUNT** |
| 1                A. 5                days after the Execution of this Agreement                                                                                                                                                                                                                                                                                                                                                                                     | $*                                |
| 1                B. The                latest date of completion of all of the following: Completion of                conversion to Hercon methodology, order components, dedicated tooling,                drawings, documentation records, testing/release; Completion of analytical                validation; and Completion of full scale-up, including non-GMP run                and                testing, and commencement of informal stability testing | $*                                |
| **Subtotal                for Stage 1**                                                                                                                                                                                                                                                                                                                                                                                                                                  | **$***                            |
| 2                A.  Initiation                of clinical trial batch manufacture                                                                                                                                                                                                                                                                                                                                                                                  | $*                                |
| 2                B.  Completion                of Phase 2 dose-ranging study clinical trial batch manufacture, completion                of testing/release, commencement of stability testing                                                                                                                                                                                                                                                                      | $*                                |
| 2                C.  Completion                of 3 months accelerated and non-accelerated stability testing, with                2 year                room temperature testing ongoing                                                                                                                                                                                                                                                                            | $*                                |
| **Subtotal                for Stage 2**                                                                                                                                                                                                                                                                                                                                                                                                                                  | **$***                            |
| 3                A.  Initiation                of clinical trial batch manufacture                                                                                                                                                                                                                                                                                                                                                                                  | $*                                |
| 3                B.  Completion                of Phase 3 pivotal study clinical trial batch manufacture, completion                of                testing/release, commencement of stability testing                                                                                                                                                                                                                                                            | $*                                |
| **Subtotal                for Stage 3**                                                                                                                                                                                                                                                                                                                                                                                                                                  | **$***                            |
| **TOTAL**                                                                                                                                                                                                                                                                                                                                                                                                                                                                | **$***                            |

|   | Milestone                payments reflect the total cost of Nitroglycerin Adhesive Mixture,                materials and effort to complete Processing of the Clinical Trial                Products. Hercon recognizes that unexpected difficulties may arise                during                any stage of this work, and guarantees and agrees that the milestone                payments will never exceed the payments specified in Section                3.1. |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**ARTICLE      4**

**MANUFACTURING      CLINICAL TRIAL PRODUCTS**

| 4.1 | **Clinical                Trial Products Supply and Purchase Obligations.**                CTI understands and agrees that Hercon does not warrant or commit                that the                Clinical Trial Products will receive applicable regulatory approval                or be                successfully marketed and commercialized. For the life of the patents                referenced in the Recitals to this Agreement, Hercon is precluded                from                manufacturing or supplying the Clinical Trial Products to any Person                other                than CTI or any licensee or transferee of CTI’s Intellectual                Property. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.2 | **Manufacturing                Practices.** |
|-----|---------------------------------------------|

| (a) | **Clinical                Trial Product Specifications.**                Hercon shall manufacture, fill, assemble, warehouse and otherwise                Process                (except for labeling) the Clinical Trial Products in conformity with                the                Product Specifications and in accordance with all applicable laws                and                regulations, including the U.S. Federal Food, Drug and Cosmetic                Act,                21 U.S.C. §301 *et                seq*.                and regulations promulgated thereunder. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b) | **GMP.**                Hercon shall manufacture the Clinical Trial Products in accordance                with                GMP. Hercon shall advise CTI in writing of any proposed process changes                that have regulatory implications prior to their implementation by                Hercon.                CTI shall have the right, at its sole expense, to audit Hercon for                compliance with GMP on reasonable notice during normal business hours                at                least once in each calendar year, and more often in CTI’s reasonable                discretion. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c) | **Nitroglycerin                Adhesive Mixture.**                Hercon shall supply and use the Nitroglycerin Adhesive Mixture by                sourcing                such ingredient from the third party base supplier set forth in the                Product Specifications. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d) | **Certificates                of Analysis.**                Hercon shall provide CTI with a certificate of analysis for each                shipment                of the Clinical Trial Products manufactured and supplied hereunder                based                upon a reference standard established by Hercon and reasonably acceptable                to CTI. Such certificate of analysis shall, at a minimum, list the                tests                performed by or on behalf of Hercon, test specifications and test                results.                In addition, a statement will be made that the Clinical Trial Products                were manufactured in accordance with                GMP(s). |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e) | **Quality                Control Information.**                Hercon shall perform quality control tests to ensure that the Clinical                Trial Products are produced in accordance with GMP and all applicable                laws                and regulations, including the U.S. Federal Food, Drug and Cosmetic                Act,                21 U.S.C. §301 *et                seq*.                and regulations promulgated thereunder, and                conform to the Product Specifications. Upon the written request of                CTI,                Hercon shall provide CTI with the results of such quality control                tests                and such other information, including other analytical and manufacturing                documentation, reasonably requested by CTI, regarding quality control                of                the Clinical Trial Products supplied hereunder. Hercon                shall notify CTI as soon as practicable after Hercon identifies any                manufacturing or testing deviations, and shall provide CTI with complete                records of any investigations, reports and the like pertaining to                such                deviations. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (f) | **Packaging                Control.**                In                addition to its obligations pursuant to Sections 4.2 (d) and (e),                Hercon                will evaluate and inspect each batch of Clinical Trial Products in                accordance with Packaging guidelines set forth in the Product                Specifications and will provide CTI with a Clinical Trial Products                lot                release. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (g) | **Compliance                with Laws.**                Hercon shall develop and manufacture all Clinical Trial Products                in                accordance with the Product Specifications. All Clinical Trial Products                shall be stored and packaged in accordance with the requirements                of all                applicable laws and the rules and regulations of the FDA or other                regulatory authority promulgated thereunder. Clinical Trial Products                shall, at the time of shipment and while in the custody and control                of                Hercon, not be adulterated, misbranded, misused, contaminated, tampered                with or otherwise altered, mishandled, or subjected to negligence                and                shall conform to the Product                Specifications. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (h) | **Inspection.**                CTI, or its designee, may, at its own expense, with prior reasonable                notice and during regular business hours, visit the facilities used                by                Hercon to manufacture, store or otherwise Process Clinical Trial                Products                to (i) review the Clinical Trial Products related records and the                facilities, (ii) inspect, observe and audit the Processing of Clinical                Trial Products, and (iii) examine the condition of the Clinical Trial                Products and materials used in the                Processing. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i) | **Sample                Retention.**                Hercon shall retain samples of each batch of Clinical Trial Products                at                Hercon’s facility at no cost to CTI until the date that is three (3) years                after completion of Processing of each such batch (or for such longer                period as may be required by applicable regulatory authorities or                applicable laws or regulations). |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.3 | **Labeling                and Packaging.** |
|-----|--------------------------------------------|

| (a) | **Labeling.**                The Clinical Trial Products will be labeled by a third party provider                nominated by CTI. Hercon shall label corrugated cases and pain white                cartons in regards to the dose, however Hercon will not be required                to                provide full labeling required for clinical trial purposes. Other                than the                labeling described in 4.3(a), Hercon shall have no liability for                misbranding or otherwise arising out of or relating to the labeling                of the                Clinical Trial Products. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b) | **Packaging.**                Hercon shall supply Packaging which includes, at a minimum, plain                white                packaging and plain white cartons packaged in corrugated cases. Hercon                shall supply Packaging for the Clinical Trial Products under this                Agreement and such Packaging shall be in accordance with the Product                Specifications as provided herein and all applicable laws and                regulations. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 4.4 | **Delivery                and Acceptance.** |
|-----|---------------------------------------------|

| (a) | **Delivery.**                All Clinical Trial Products supplied under this Agreement shall be                shipped                F.O.B. Emigsville, PA in such quantities, on such dates, with such                carrier, to such designation, and in accordance with such other                requirements as are specified by CTI in the applicable purchase order.                CTI                shall pay all freight, insurance charges, taxes, import and export                duties,                inspection fees and/or other charges applicable to the sale and transport                of Clinical Trial Products purchased by CTI hereunder prior to delivery                thereof by Hercon to such CTI designated location. Title and risk                of loss                and damages to Clinical Trial Products purchased by CTI hereunder                shall                pass to CTI upon delivery to CTI’s designated carrier F.O.B. Hercon’s                facility in Emigsville, PA. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b) | **Rejection                and Cure.**                If                a shipment of Clinical Trial Products or any portion thereof (i)                fails to                conform to the applicable Product Specifications, (ii) was not Processed                in accordance with applicable laws or regulations or GMP, or (iii)                is                delivered with a material shortage or any overage of Clinical Trial                Products, then CTI shall have the right to reject such nonconforming                shipment of Clinical Trial Products or the nonconforming portion                thereof,                as the case may be. CTI shall give written notice to Hercon of its                rejection hereunder, within thirty (30) days after CTI’s receipt of such                shipment, specifying the grounds for such rejection; provided, however,                that in the event such defect is latent or was not obvious and could                not                be readily discovered from a physical inspection of the Clinical                Trial                Products shipment, CTI may give written notice to Hercon of its rejection                of such shipment within sixty (60) days after CTI's discovery of                such                non-conformance. The nonconforming shipment of Clinical Trial Products,                or                the nonconforming portion thereof, shall be held for Hercon’s disposition,                or shall be returned to Hercon, in each case at Hercon’s expense, as                directed by Hercon. Hercon shall use its commercially reasonable                efforts                to replace each nonconforming shipment of Clinical Trial Products,                or the                nonconforming portion thereof, with conforming Clinical Trial Products                as                soon as reasonably practicable after receipt of notice of rejection                thereof, and in any event shall do so within ninety (90) days after                the                receipt of replacement Nitroglycerin Adhesive Mixture*** ***which                shall be ordered no later than thirty (30) days after receipt of                notice of                rejection thereof. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (c) | **Warranty.**                Hercon warrants that (a) Clinical Trial Products manufactured                hereunder shall conform with the Product Specifications; (b) Clinical                Trial Products shall be manufactured hereunder in accordance with                all                applicable laws and regulations, GMP and the Regulatory Dossiers;                (c) all                raw materials, including, without limitation, the Nitroglycerin Adhesive                Mixture, and all Clinical Trial Products will not be adulterated,                misbranded, misused, contaminated, tampered with or otherwise altered,                mishandled, or subjected to negligence while in the custody and control                of                Hercon or otherwise violate the rules and regulations of the FDA;                (d)                Hercon and its officers, directors, employees, Affiliates, contractors                and                agents have not been debarred or convicted of a crime which could                lead to                debarment, and Hercon will not use in any capacity the services of                any                Person debarred or convicted of a crime that could lead to debarment                under                Subsection 306(a) or (b) of the Generic Drug Enforcement Act of 1992,                and                neither Hercon nor its officers, directors, employees, Affiliates,                contractors or agents or other Person used by Hercon in any services                hereunder are or have been subject to any other penalty or sanction                by the                FDA; (e) Hercon will not transfer or supply any Clinical Trial Products                to                any Person other than CTI except as required by applicable law, regulation                or legal process; and (f) the Process shall not infringe the patent                rights                of any Person or constitute a misappropriation of the trade secrets                or                other intellectual property rights of any Person, except for any                such                infringement or misappropriation arising directly from Hercon’s use of                CTI’s Intellectual Property or any failure of CTI’s Intellectual Property                to be fully valid or to fully protect the Clinical Trial Products                from any                such claim of infringement or misappropriation (collectively, parts                (a),                (b) and (c) above comprise the “Limited Warranty”). |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**ARTICLE      5**

**FURTHER      OBLIGATIONS OF THE PARTIES**

| 5.1 | **Drug                Master File, Regulatory Dossiers**.                Hercon shall provide CTI with such assistance as CTI shall reasonably                request to obtain a right of reference to the Drug Master File of                any                third-party supplier of the Nitroglycerin Adhesive Mixture and other                raw                materials for the Clinical Trial Products designated from time to                time by                CTI. The Product NDA and all Regulatory Dossiers shall be owned by                CTI and                Hercon shall have no rights                therein. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 5.2 | **Facility                Qualification**.                In addition to Hercon’s responsibilities set forth hereunder, Hercon                shall, at no cost to CTI, take all such actions to qualify (and thereafter                to maintain qualification of) the facility (or facilities) at which                Hercon                Processes Clinical Trial Products hereunder, as required under applicable                law and regulations in the United States and each other country in                the                Territory, to enable CTI to obtain and maintain all applicable Regulatory                Dossiers for the Clinical Trial Products, including the Product NDA,                consistent with the requirements of the FDA and other applicable                regulatory authorities in the                Territory. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.3 | **Further                Obligations of Hercon**.                During the term of this Agreement, Hercon                shall: |
|-----|----------------------------------------------------------------------------------------------------------------------------------|

|   | 5.3.1 | At                its own expense, promptly respond to all reasonable inquiries from                CTI. |
|--------|-------|----------------------------------------------------------------------------------------------------------|

|   | 5.3.2 | Without                limiting the other provisions of this Agreement, use its commercially                reasonable efforts at all times to minimize the development                time. |
|--------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 5.3.3 | Furnish                or otherwise make available to CTI current copies of all issued master                batch records, procedures, specifications and methods and standard                operating procedures related to the Clinical Trial Products that                are                material to regulatory filings and submit to CTI prior to implementation                any and all proposed changes to the same that are material to regulatory                filings. |
|--------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 5.3.4 | Furnish                or otherwise make available to CTI prior to implementation any proposed                manufacturing changes related to the Clinical Trial Products which                may                affect regulatory status, such as suppliers of raw material used                in the                Clinical Trial Products, containers, Packaging, Labeling, Product                Specifications, manufacturing process, testing or the facilities                which are                related to the manufacturing of Clinical Trial Products. Notwithstanding                anything to the contrary herein, no change in the Product Specifications,                manufacturing processes, test methods, or other documentation or                procedures relating to Processing of Clinical Trial Products shall                be                implemented by Hercon unless and until the Parties have executed                a written                agreement documenting such change. |
|--------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 5.3.5 | Promptly                notify CTI in writing of any comments, responses or notices received                from                the FDA, or other applicable regulatory authorities, which relate                to or                may impact the Clinical Trial Products or the manufacture of the                Clinical                Trial Products. Without limiting the foregoing, Hercon                shall advise CTI no later than the next day that is not a Saturday,                Sunday                or federal or state holiday if an authorized agent of any regulatory                authority plans to visit Hercon’s facility, and makes an inquiry regarding                Hercon’s                Processing of Clinical Trial Products or regarding any part of                the                facility that is used in Processing of Clinical Trial Products. CTI                shall                have the right to be present at any visit relating to the Clinical                Trial                Products and to review in advance and comment on any response by                Hercon to                the communication or investigation relating to Clinical Trial Products.                Hercon shall provide to CTI copies of any Form 483s or equivalent                documents delivered by such regulatory authority as a result of such                visit                and, at its own cost, obtain and maintain any and all Federal and                state                regulations and/or licenses with respect to Hercon's manufacture                of the                Clinical Trial Products. |
|--------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 5.3.6 | Provide                ongoing technical product support with respect to the Clinical Trial                Products. |
|--------|-------|----------------------------------------------------------------------------------------------------------------------|

**ARTICLE      6**

**REPRESENTATIONS      AND WARRANTIES**

| 6.1 | **Representations                and Warranties**.                Each party hereby represents and warrants to the other party as                follows: |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | **Corporate                Existence**.                Such party is a corporation duly organized, validly existing and                in good                standing under the laws of the jurisdiction in which it is                incorporated. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | **Authorization                and Enforcement of Obligations**.                Such party (a) has the corporate power and authority and the legal                right                to enter into this Agreement and to perform its obligations hereunder,                and                (b) has taken all necessary corporate action on its part to authorize                the                execution and delivery of this Agreement and the performance of its                obligations hereunder. This Agreement has been duly executed and                delivered                on behalf of such party, and constitutes a legal, valid, binding                obligation, enforceable against such party in accordance with its                terms. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | **Consents**.                All necessary consents, approvals and authorizations of and notices                to all                governmental authorities and other Persons required to be obtained                or                provided by such party in connection with its performance of this                Agreement have been obtained or                provided. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | **No                Conflict**.                The execution and delivery of this Agreement and the performance                of such                party’s obligations hereunder (a) do not conflict with or violate any                requirement of applicable laws or regulations, and (b) do not conflict                with, or constitute a default under, any contractual obligation of                such                party. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**ARTICLE      7**

**INDEMNIFICATION;      INSURANCE**

| 7.1 | **Hercon’s                Indemnity Obligations**.                Hercon shall defend, indemnify and hold harmless CTI, its Affiliates                and                their respective successors and permitted assigns (and the respective                officers, directors, stockholders, partners and employees of each)                from                and against any and all losses, liabilities, claims, actions, proceedings,                damages and expenses (including without limitation reasonable attorneys’                fees and expenses) (herein “Damages”) relating to or arising from (a)                Hercon's performance of or failure to perform its obligations under                this                Agreement, including, without limitation, all data and other information                provided to CTI for use in the preparation and filing of the Product                NDA,                (b) any breach by Hercon or its Affiliates, subcontractors or agents                of                this Agreement, (c) the negligence or willful misconduct of any officers,                directors, partners or employees of Hercon or its Affiliates,                subcontractors or agents, or (d) any claims of infringement or                misappropriation relating to any intellectual property used by Hercon                (expressly excluding CTI’s Intellectual Property) in the fulfillment of                its obligations under this Agreement, including, without limitation,                any                modifications to CTI’s Intellectual Property without CTI's prior written                consent. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**CTI’s        Indemnity Obligations.**

| 7.2 | **Procedure**.                A                party (the indemnitee) that intends to claim indemnification under                this                Article 7 shall notify the other party (the “indemnitor”) promptly in                writing of any action, claim or liability in respect of which the                indemnitee believes it is entitled to claim indemnification, provided                that                the failure to give timely notice to the indemnitor shall not release                the                indemnitor from any liability to the indemnitee except to the extent                the                indemnitor is prejudiced thereby. The indemnitor shall have the right,                by                written notice to the indemnitee, to assume the defense of any such                action                or claim within the fifteen (15) day period after the indemnitor’s receipt                of notice of any action or claim with counsel of the indemnitor’s choice                and at the sole cost of the indemnitor. If the indemnitor so assumes                such                defense, the indemnitee may participate therein through counsel of                its                choice, but at the sole cost of the indemnitee. The party not assuming                the                defense of any such claim shall render all reasonable assistance                to the                party assuming such defense, and all reasonable out-of-pocket costs                of                such assistance shall be for the account of the indemnitor. No such                claim                shall be settled other than by the party defending the same, and                then only                with the consent of the other party which shall not be unreasonably                withheld; provided that the indemnitee shall have no obligation to                consent                to any settlement of any such action or claim which imposes on the                indemnitee any liability or obligation which cannot be assumed and                performed in full by the indemnitor, and the indemnitee shall have                no                right to withhold its consent to any settlement of any such action                or                claim if the settlement involves only the payment of money by the                indemnitor or its insurer. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.3 | **Insurance**.                Hercon shall obtain, at its expense, property, commercial and liability                insurance covering its obligations hereunder, in each case in amounts                appropriate to the conduct of its business. Without limiting the                foregoing, Hercon shall use reasonable efforts to obtain and maintain                in                force at all times during the term of this Agreement third party                liability                insurance in reasonably prudent amounts in respect of the risks of                which                it is providing indemnity hereunder, with a reputable insurance carrier                or                by self-insurance. Hercon shall make available to CTI, at CTI’s request,                evidence of its maintenance of insurance in satisfaction of its                obligations under this Section 7.3. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**ARTICLE      8**

**RELATIONSHIP      BETWEEN THE PARTIES**

| 8.1 | **Independent                Contractor**.                The relationship between Hercon and CTI is solely that of buyer and                seller, it being understood that each party is acting as an independent                contractor for its own account and this Agreement does not establish                a                joint venture, agency, partnership or employer/employee relationship                between the parties. Neither party shall have authority to conclude                contracts or otherwise to act for or bind the other party in any                manner,                whatsoever, as agent or otherwise. Any and all contracts and agreements                entered into by either party shall be for that party’s sole account and                risk and shall not bind the other party in any                respect. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**ARTICLE      9**

**CONFIDENTIALITY      AND PUBLIC DISCLOSURE**

| 9.1 | **Mutual                Confidentiality**.                Except as may be required to obtain government approval to manufacture,                sell or use the Clinical Trial Products, Hercon and CTI will treat                as                confidential the Confidential Information, and will take all necessary                precautions to assure the confidentiality of such information. Each                party                agrees to return to the other upon the expiration or termination                of this                Agreement all Confidential Information acquired from the other except                as                to such information it may be required to retain under applicable                law or                regulation, and except for one copy of such information to be retained                by                the other party’s legal department or legal counsel. Neither party shall,                during the period of this Agreement and for five (5) years thereafter,                without the express prior written consent of the other party use                or                disclose any such Confidential Information for any purpose other                than to                carry out its obligations hereunder. Both parties, prior to disclosure                of                such Confidential Information to any employee, consultant or advisor                shall                ensure that such person is bound in writing to observe the confidentiality                provisions of this Agreement. The obligations of confidentiality                shall not                apply to information that Hercon or CTI is required by law or regulation                to disclose, provided however that the disclosing party shall so                notify                the other party in writing in advance of such required disclosure                and                shall cooperate with the other party on reasonable measures to protect                the                confidentiality of the information. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.2 | **Public                Disclosure**.                No announcement, news release, public statement, publication, or                presentation relating to the existence of this Agreement, the subject                matter hereof, or either party’s performance hereunder will be made                without the other party’s prior written approval, which approval shall not                be unreasonably withheld. The parties agree that they will use reasonable                efforts to agree on the text, and to coordinate the release, of a                press                release relating to the existence of this Agreement so that such                initial                announcement or press release by each is made contemporaneously. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 9.3 | **Remedies**.                Because of the unique nature of the Confidential Information, the                receiving party acknowledges and agrees that the disclosing party                may                suffer irreparable injury if the receiving party fails to comply                with the                obligations set forth in this Article 9, and that monetary damages                may be                inadequate to compensate the disclosing party for such breach.                Accordingly, the receiving party agrees that, in addition to any                other                remedies available at law, in equity or otherwise, the disclosing                party                will be entitled to seek injunctive relief and/or specific performance,                without the requirement of posting a bond or proving actual damages,                to                enforce the terms, or prevent or remedy the violation, of this Article                9.                This provision shall not constitute a waiver by either party of any                rights                to damages or other remedies which it may have pursuant to this Agreement                or otherwise. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**ARTICLE      10**

**INVENTIONS      AND WORK PRODUCT**

| 10.1 | **Inventions**.                Hercon shall disclose in writing to CTI any invention, development,                information or idea, whether patentable or not, made or conceived                by                Hercon or any of its employees or consultants, in the course of performing                or that arise out of the performance of Hercon’s obligations hereunder,                including those relating solely to the Clinical Trial Products, Processing                of Clinical Trial Products or relating solely to or arising solely                from                the Confidential Information or Intellectual Property of CTI                (collectively, the “Inventions”). Hercon shall make such disclosure to CTI                promptly after the conception or reduction to practice of any Inventions.                All Inventions shall be the sole and exclusive property of CTI and                Hercon                hereby expressly and irrevocably conveys and assigns, and shall cause                its                Affiliates and its and their employees and agents, as applicable,                to so                convey and assign, to CTI any and all rights, title and interest                they may                have in and to such Inventions. Assignment and transfer of all such                Inventions shall occur instantly and automatically upon the development,                making, conception or reduction to practice of such Inventions and                shall                not require any further deeds or documents to be exchanged between                the                Parties; provided, however, that upon CTI’s request, Hercon shall execute,                acknowledge and deliver, and shall cause its employees and consultants                to                execute, acknowledge and deliver, all applications, assignments and                other                instruments which CTI (or its nominee) shall deem reasonably necessary                to                apply for, obtain, protect, perfect or enforce CTI’s ownership of all                rights, title, and interest in the Inventions, including as necessary                to                apply for and obtain invention rights, patents, patent applications,                letters patent, copyrights and reissues thereof (“Rights”) in the United                States and foreign countries. Hercon shall execute, acknowledge and                deliver, and shall cause its employees and consultants to execute,                acknowledge and deliver, all such further papers as CTI may reasonably                request to enable CTI (or its nominee) to publish or protect Inventions                and render such further assistance as CTI may reasonably request                in the                prosecution of Rights and in any patent office proceeding or litigation                involving Inventions. All Intellectual Property and know-how regardless                of                origin associated with the Clinical Trial Products shall be the sole                and                exclusive property of CTI and any inventions shall be duly assigned                to                CTI. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.2 | **Injunctive                Relief**.                Hercon acknowledges and agrees that, because of the unique and                extraordinary nature of the development obligations, any breach or                threatened breach of the provisions of Section 10.1 hereof would                cause                irreparable injury and incalculable harm to CTI and CTI shall,                accordingly, be entitled to injunctive and other equitable relief                for such                breach or threatened breach, without the requirement of posting a                bond or                proving actual damages, and that resort by CTI to sue for injunctive                or                other equitable relief shall not be deemed to waive or to limit in                any                respect any other right or remedy which CTI may have with respect                to such                breach or threatened breach. The parties agree that in the event                of any                action, suit or proceeding at law or in equity brought to enforce                the                covenants contained in Section 10.1 hereof, or to obtain money damages                for                breach thereof, the party prevailing in any such action, suit or                proceeding shall be entitled upon demand to reimbursement from the                other                party for all expenses (including, without limitation, reasonable                attorney’s fee and disbursements) incurred in connection                therewith. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**ARTICLE      11**

**TERM      AND TERMINATION**

| 11.1 | **Term**.                Unless terminated earlier pursuant to Section 11.2 below, the term of                this Agreement (the “Term”) shall expire two (2) years from the date of                this Agreement. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2 | **Termination**. |
|------|------------------|

**By      Either party or Both Parties**

|   | (i) | This                Agreement may be terminated immediately upon mutual written consent                of                both Parties upon mutually accepted terms;                or |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (ii) | Either                party shall have the right to terminate this Agreement upon giving                written                notice of termination to the other party, after the breach of any                material                provision of this Agreement by the other party if the other party                has not                cured such breach within thirty (30) days after receipt of written                notice                thereof from the non-breaching party;                or |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**By      CTI**

|  | (i) | CTI                shall have the right to terminate this Agreement at any time for                any                reason upon giving written notice of termination to                Hercon. |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Rights      and Remedies Upon Expiration or Termination**

----

**Technology      Transfer**

**ARTICLE      12**

**NON-COMPETE**

----

**ARTICLE      13**

**MISCELLANEOUS**

| 13.1 | **Notices**.                All notices or other communications given pursuant hereto by one                party                hereto to the other party shall be in writing and deemed given (a)                when                delivered by messenger, (b) when sent by fax, (with receipt confirmed),                (c) when received by the addressee, if sent by Express Mail, Federal                Express or other express delivery service (receipt requested), or                (d) five                days after being mailed in the U.S., first-class postage prepaid,                registered or certified, in each case to the appropriate addresses                and fax                numbers set forth below (or to such other addresses and fax numbers                as a                party may designate as to itself by notice to the other                party): |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.2 | **Assignment**.                Neither party shall, without the prior written consent of the other                party                (not to be unreasonably withheld or delayed), assign or transfer                this                Agreement to any Person, in whole or in part, provided that, each                party                may assign or transfer this Agreement to any Affiliate or to any                successor in interest (whether by merger, acquisition, asset purchase                or                otherwise) to all or substantially all of its business to which this                Agreement relates                without the prior written consent of the other party hereto. All                of the                terms and provisions of this Agreement shall be binding upon and                inure to                the benefit of and be enforceable by the parties hereto and their                respective permitted successors and                assigns. |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.3 | **Severability**.                If any portion of this Agreement is held invalid by a court of competent                jurisdiction, such portion shall be deemed to be of no force and                effect                and this Agreement shall continue in full force and effect without                said                portion(s), consistent with the intent of the Parties at the time                of its                execution, provided however, if the deletion of such provision materially                impairs the commercial value of this Agreement to either party, the                parties shall attempt to renegotiate such provision in good                faith. |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.4 | **Entire                Agreement**.                This Agreement and all Exhibits and Schedules attached hereto and                thereto                contain the sole and entire agreement and understanding of the parties                hereto and their respective Affiliates and representatives related                to the                subject matter hereof and supersede all oral or written agreements                concerning the subject matter made prior to the date of this Agreement. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.5 | **Amendments,                Waivers**.                This Agreement may not be amended, changed, modified or supplemented                orally, and no amendment, change, modification or supplement of this                Agreement shall be recognized nor have any effect, unless the writing                in                which it is set forth is signed by Hercon and CTI, nor shall any                waiver of                any of the provisions of this Agreement be effective unless in writing                and                signed by the party to be charged therewith. The failure of either                party                to enforce, at any time, or for any period of time, any provision                hereof                or the failure of either party to exercise any option herein shall                not be                construed as a waiver of such provision or option and shall in no                way                affect that party’s right to enforce such provision or exercise such                option. No waiver of any provision hereof shall be deemed to be,                or shall                constitute, a waiver of any other provision, or with respect to any                succeeding breach of the same                provision. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 13.6 | **Governing                Law, Dispute Resolution**.                This Agreement shall be governed by, and construed in accordance                with, the                laws of the State of Delaware and the United States, as though made                and to                be fully performed therein without regard to conflicts of laws and                principles thereof. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | The                parties shall initially attempt in good faith to resolve any significant                controversy, claim, allegation of breach or dispute arising out of                or                relating to this Agreement (hereinafter collectively referred to                as a                “Dispute”) through negotiations between senior executives of CTI and                Hercon. If any Dispute is not resolved through such negotiations,                each                party irrevocably and unconditionally consents to the exclusive                jurisdiction of the courts of general jurisdiction of the State of                Delaware and the United States District Court for the District of                Delaware                for any action, suit or proceeding relating to a Dispute, and agrees                not                to commence any such action, suit or proceeding except in such courts.                Each Party further irrevocably and unconditionally waives any claim                that                such action, suit or proceeding has been brought in an inconvenient                forum                or should be brought in any other venue to which such party may be                entitled by virtue of domicile or                otherwise. |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.7 | **Singular                and Plural Forms**.                The use herein of the singular form shall also denote the plural                form, and                the use herein of the plural form shall denote the singular form,                as in                each case the context may require. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.8 | **Headings**.                The headings contained in this Agreement are for convenience of reference                only and shall not constitute a part hereof or define, limit or otherwise                affect the meaning of any of the terms or provisions                hereof. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.9 | **Counterparts**.                This Agreement may be executed in one or more facsimile or original                counterparts, each of which shall be deemed an original, but all                of which,                when taken together, shall constitute one and the same                instrument. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.10 | **Force                Majeure**.                If either party is prevented from complying, either totally or in                part,                with any of the terms or provisions of this Agreement, by reason                of force                majeure, including, but not limited to, fire, flood, earthquake,                explosion, storm, war, rebellion, acts of God and/or other causes                or                externally induced casualty beyond its reasonable control and without                its                negligence, whether similar to the foregoing matters or not, then,                upon                written notice by the party liable to perform to the other party,                the                requirements of this Agreement or such of its provisions as may be                affected, and to the extent so affected, shall be suspended during                the                period of such disability; provided that the party asserting force                majeure                shall bear the burden of establishing the existence of such force                majeure                by clear and convincing evidence; and provided further, that the                party                prevented from complying shall use its best efforts to remove such                disability within thirty (30) days and shall continue performance                with the                utmost dispatch whenever such causes are removed and shall notify                the                other party of the event not more than five (5) days from the time                of the                event. When such circumstances arise, the parties shall discuss what,                if                any, modifications to the terms of this Agreement may be required                in order                to arrive at an equitable solution. Notwithstanding the foregoing,                in the                event that a material event of force majeure shall continue for a                period                of longer than sixty (60) days, then the party unaffected by such                event                may terminate this Agreement by not less than fifteen (15) days'                written                notice of termination to the other party; provided that, if the force                majeure event ceases within such fifteen day period, this Agreement                shall                remain in full force and effect. |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

***[Signatures      on Next Page]***

----

----

----